| Main Subject |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Outsourcing > Outsourced Chiropractic Billing Service Performance Index - June 2006 |
|
Main Subject - Outsourced Chiropractic Billing Service Performance Index - June 2006
Benchmark-driven performance management helps establish objective industry standards. Medical service providers can use benchmarking to evaluate performance According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product of their billing service and measure their improvement over time. This article presents a prototype for a rule-based chiropractic index, including its covera ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in e definition, update cycle, volume weighting, and provided information. Current (June 2006) Billing Precision Index (BPI) stands at 18, which means that the lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. average of ten top performing payers working with BPI clients have 18% of Accounts Receivable beyond 120 days. This is a key billing performance characterist here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe c, as it is a proxy of the claims that are never paid. Obviously, the lower is the index the better is billing performance. The table below also lists the t d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro p ten performing payers and their relative index as recorded in Billing Precision's system ( BillingP ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc recision.com ).
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi Blue Shield Florida 5
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically 11
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ 18
Coverage BPI ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi s rule-based, i.e., payer participation in the index is defined by dynamically rules at the time of computation and not by a static listing of specific payers ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a . Therefore, any specific payer may start or discontinue participation in the index, dependent on satisfaction of rule's conditions. Current selection of pa dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod ers for participation in the BPI is based on fifty top-volume providers across all United States that have received Billing Precision services for more than s cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin ix months and have more than two hundred claims in their current Accounts Receivable. Update Cycle Billing Precision updates its index on a monthly tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen basis. Volume Weighting BPI is volume weighted, which is important to accomodate future growth of provided information, index combinations, and sen t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel itivity across multiple indices. Information Provided BPI computes the percent of Accounts Receivable beyond 120 days. Note that national average ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust across all medical specialties of percent of accounts receivable beyond 120 days is 17.7%. Summary Medical Billing Performance Index helps the deve y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products opment of billing industry standards. Medical service providers can use the index to benchmark their billing performance and to guide its improvement over ti . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de me. Rule-based index definition allows for automated inclusion and exclusion of payers in the index based on payer attributes, such as numbers of processed c elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip aims, accounts receivable distribution, certain mix of CPT codes, or patient demographics. Relative payer index provides billing process improvement direction tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Motivating Tips for Job Seekers Interview Perspectives - The Interviewer Who Wouldn't Interview The Efficient Trade Show Planner's Guide to Vendor Registration
|